August 1, 2023 August is National “Make-a-Will-Month” — the time when we are reminded of the importance of thinking ahead to leave your mark on the world with a meaningful legacy to your family and community. A will is the easiest and most effective means to ensure that you fully provide for the people you […] READ MORE
NEW YORK, NY. August 2, 2023. The Lupus Research Alliance (LRA) is pleased to announce that the 2023 Global Team Science Award (GTSA) has been granted to an exceptional multidisciplinary research team of experts in immunology, pediatric rheumatology and nephrology, genetics, and data analysis to identify drivers of lupus nephritis in children with the aim […] READ MORE
July 25, 2023 The Lupus Research Alliance extends heartfelt condolences to the wife, Susan, and children of our former honorary Board member and legendary artist, singer, and philanthropist Tony Bennett. Tony was an active supporter for our legacy organization, the SLE Lupus Foundation, as a friend of its founder Susan Golick, a pioneer in lupus […] READ MORE
July 19,2023 The LRA is pleased to share news announced by Aurinia Pharmaceuticals of published results showing that the lupus treatment, voclosporin (Lupkynis) preserved kidney function up to three years among lupus nephritis. These results of the Phase 3, double-blind, placebo-controlled AURORA 2 extension study were published in the official peer-reviewed professional journal of the […] READ MORE
SUMMIT, N.J., July 17, 2023 /PRNewswire/ — Former Super Bowl Champion and Mad Dog Sports radio personality Willie Colon is hosting today the 9th Annual Willie Colon Golf Outing crafted by Tito’s Handmade Vodka for the Lupus Research Alliance (LRA). The event drives lupus awareness and tees up the opening of the Fall season of the grassroots […] READ MORE
NEW YORK, NY. July 12, 2023. The Lupus Research Alliance is pleased to announce the 2023 recipients of the Career Development and Postdoctoral Awards to Promote Diversity in Lupus Research. The Diversity in Lupus Research Awards aim to foster the development of outstanding, underrepresented minority scientists and establish a diverse community of researchers and clinicians […] READ MORE
New York, NY. June 29, 2023. Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance, today announced the launch of three pilot research initiatives for Project CHANGE, a community-driven approach to address systemic challenges contributing to the underrepresentation of people of color, particularly Black people, in lupus clinical trials. The sites selected to […] READ MORE
Rituximab biosimilar BCD020 showed effectiveness in treating lupus nephritis in a pediatric population according to results of a retrospective study published in the journal Biomedicines. A biosimilar is a medication that is as the name suggests very similar to the drug already approved – in this case rituximab. A retrospective study looks back at information […] READ MORE
NEW YORK, NY – June 22, 2023 – The Lupus Research Alliance awarded its 2023 Lupus Insight Prize to Carola Vinuesa, MD, PhD, of The Francis Crick Institute, for her seminal discovery that a mutation in a specific human gene causes systemic lupus erythematosus (SLE), uncovering an important target for the development of novel treatment. […] READ MORE
NEW YORK, N.Y. — June 2, 2023 Lupus Therapeutics announced the start of a collaboration to conduct three Phase 3 clinical trials testing an investigational therapeutic ianalumab for systemic lupus erythematosus and lupus nephritis. Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance, will help Novartis Pharmaceuticals Corporation (Novartis) conduct the trials through […] READ MORE
June 1, 2023 What a month May was! As we reflect upon Lupus Awareness month, the community continues to inspire. We celebrate how ManyOne Can make a difference, and we salute all the accomplishments of those that ARE making a difference every day. Thank you for your dedication and support! Together, the community has: Advanced […] READ MORE
May 31, 2023 We are pleased to share encouraging news from EULAR, the annual meeting of the European Alliance of Associations for Rheumatology of Phase 2 data presented showing that upadacitinib improved SLE disease activity and time to first flare while lowering the need for steroids. Side effects were consistent with the known safety profile. Discovered and […] READ MORE
